Comparing the current results to its competitors, Marinus Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2024 by 16.39 % year on year. The revenue growth was below Marinus Pharmaceuticals Inc 's competitors' average revenue growth of 20.03 %, achieved in the same quarter.
Marinus Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 109.16 %
Marinus Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company competes primarily with pharmaceutical and biotechnology firms developing clinical-stage therapies or marketing drugs for similar indications. Competitors often have advantages including larger size, greater cash flow, established commercial infrastructure, clinician relationships, institutional experience, and more extensive financial, technical, and human resources, as well as longer histories of marketed products. These competitors may develop drugs that are safer, more effective, more widely used, less costly, and more successful in manufacturing and marketing, potentially rendering the company's product, ganaxolone, obsolete or non-competitive. Standard treatments for status epilepticus (SE) patients include benzodiazepines as first-line therapy, followed by second-line intravenous antiepileptic drugs such as levetiracetam, fosphenytoin, lacosamide, or valproate. The effectiveness of these treatments was evaluated in the 2019 multicenter randomized clinical trial known as ESETT.
August 3, 2024
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), a biopharmaceutical company specializing in innovative therapies for neuropsychiatric disorders, has recently found itself at the center of a class action lawsuit. Filed by the Pomerantz Law Firm, this case underscores not only the financial implications for the company and its shareholders but also highlights issues of corporate governance and accountability within the rapidly evolving pharmaceutical industry. The following article aims to provide a comprehensive analysis of the situation, the potential ramifications for all parties involved, and the broader context of shareholder rights within corporate America. Key Details of the Lawsuit On August 3, 2024, Pom...
May 17, 2024
In a recent press release, Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) has announced significant advancements in its research and development efforts for the treatment of seizures associated with tuberous sclerosis complex (TSC). The pharmaceutical company reported the completion of enrollment for its global Phase 3 TrustTSC trial, evaluating the efficacy of oral ganaxolone in both children and adults with TSC.Tuberous sclerosis complex is a rare genetic disorder that causes benign tumors to grow in various organs, including the brain. This condition can lead to seizures in affected individuals, which can have a severe impact on their quality of life. With limited treatment options currently available, the c...
May 2, 2024
In an integral new development, Marinus Pharmaceuticals, Inc., a pharmaceutical corporation focusing on crafting innovative therapeutics for seizure disorders, announced its proactive involvement in a major global healthcare conference. At the helm of this participation will be none other than Marinus s Chairman and Chief Executive Officer, Scott Braunstein, M.D., who has recently revealed that he will indulge in a fireside chat session at the forthcoming RBC Capital Markets 2024 Global Healthcare Conference - a high-profile event of the healthcare industry that can be accessed through a pre-announced online link.Situated in Radnor, Pennsylvania, Marinus Pharmaceuticals demonstrates dedication towards develo...
Publicly Traded Peers of Marinus Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc Share Performance
+93.57%
One Year
Zynerba Pharmaceuticals Inc
Profile
Zynerba Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative transdermal cannabinoid therapies. They utilize their proprietary technology to deliver cannabinoid molecules through the skin, providing targeted treatment for various medical conditions. Zynerba Pharmaceuticals aims to provide effective, safe, and convenient therapeutic options for patients in need.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Verve Therapeutics Inc is a biotechnology company specialized in developing transformative medicines that could permanently prevent cardiovascular diseases through gene editing technology. Their business model revolves around leveraging cutting-edge gene editing techniques to develop novel therapeutics targeting specific genes associated with heart diseases. By utilizing this approach, Verve aims to provide long-term solutions for individuals at risk of cardiovascular ailments, addressing a significant unmet need in the healthcare industry.
Unity Biotechnology Inc. is a biotechnology company that focuses on developing therapies to treat age-related diseases. Their business model revolves around identifying and targeting specific senescent cells to address age-related conditions like osteoarthritis, kidney disease, and ophthalmic diseases. By leveraging their expertise in cellular senescence, Unity Biotechnology aims to develop innovative treatments that have the potential to extend healthy human lifespan.
Sources:
Marinus Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Marinus Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
